Dublin, Sept. 21, 2017 -- The "World Point of Care Diagnostics Market Size and Market Share Analysis" report has been added to Research and Markets' offering.
This report estimates the point of care diagnostics testing market at $18.4 billion
World Point of Care Diagnostics Market Size and Market Share Analysis, features in-depth analysis of the market for the traditional set of point of care diagnostics tests: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, hemoglobin diagnostics, infectious disease testing and cholesterol screening. In the past 5-10 years the following tests were added: HgA1c, B-Type Natriuretic Peptide (BNP), whole-blood lactate, D-Dimer, C-Reactive Protein (CRP).
Emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices are transforming the point of care diagnostic market. The driving force behind these innovations in healthcare is to provide expedited diagnosis where the patient is seen or in the patient's home. The POC diagnostics industry will be part of a paradigm shift from curative medicine to predictive, personalized and preemptive medicine. Globally, millions of dollars are spent annually on point of care diagnostic testing, both professional testing and self-testing.
What's the size of the market opportunity in each rapid and near-patient diagnostic testing segment? Who's winning in point of care diagnostics market share? This updated superior resource, World Point of Care Diagnostics Market Size and Market Share Analysis, focuses on the global market for point of care diagnostics.
Roche, Alere, Abbott, and Siemens are among the largest companies in point of care (POC) diagnostics in terms of revenues. Together these companies make up three-fourths of the entire point of care diagnostics market. Point of care systems are designed to deliver test results in a location and timing to be useful during a patient visit. They consist of devices such as glucose meters operated by a patient or small analyzers operated in a physician office lab.
Roche dominated the point of care diagnostics market as it does in several other in IVD (in vitro diagnostics) categories. Coagulation and glucose testing are key areas. In June 2015, Roche introduced the cobas c 513 blood glucose analyzer. It is a dedicated, high-throughput HbA1c analyzer suitable for diagnosis, monitoring and risk identification of diabetes patients.
Waltham, MA-based Alere secured the second market position Alere participates in nearly all POC test segments but has a dominating position in rapid cardiac markers.
Key Topics Covered:
1: Executive Summary
2: Introduction And Overview
3: PoC Blood Glucose Tests
4: PoC Blood And Electrolytes Testing Market
5: PoC Rapid Coagulation
6: PoC Rapid Cardiac Markers
7: PoC Drug Testing
8: PoC Pregnancy And Fertility Testing
9: PoC Colon Cancer Screening/Fecal Occult Blood Testing
10: PoC Infectious Disease Testing
11: PoC Cholesterol Testing
12: PoC Cancer Tumor Marker Testing
13: PoC Urine Strip Testing
14: Miscellaneous PoC Testing
15: Issues And Trends In Point Of Care
16: Overall Global PoC Testing Market And Market Share Analysis
17: Corporate Profiles
- Abaxis
- Abbott Labs
- Abingdon Health
- Accriva
- AccuBioTech Co
- ACON
- Aerscher Diagnostics
- Alere
- Axxin
- Beckman Coulter
- Biomerica
- bioMerieux SA
- Bioptix
- biOracle Limited
- Exalenz Bioscience
- EY Laboratories
- FABPulous B.V.
- Fio Corp
- Helena Labs
- Hema Diagnostic System
- InSilixa
- Medix Biochemical
- MedMira
- Menarini Diagnostics
- Meridian BioScience
- Metaara Medical Technologies
- Nova Biomedical
- Response Biomedical
- Roche Diagnostics
- Samsung Healthcare
- Sekisui Diagnostics
- Siemens Healthcare
- Wave 80 Biosciences
- Xagenic
For more information about this report visit https://www.researchandmarkets.com/research/bh38h5/world_point_of
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Point-of-Care Diagnostics


Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Italy Fines Apple €98.6 Million Over App Store Dominance
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 



